ADC Therapeutics(US:ADCT) Newsfilterยท2024-07-30 11:15Core Viewpoint - ADC Therapeutics SA is set to report its financial results for Q2 2024 and provide operational updates during a conference call on August 6, 2024 [1] Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors through its proprietary ADC technology [2] - ADC Therapeutics' CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy, alongside multiple ADCs in clinical and preclinical development [2] Operational Details - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [3] - A live webcast of the upcoming conference call will be available on the ADC Therapeutics website, with an archived version accessible for 30 days post-call [1]